A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | 製品名 | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T9910 | Rituximab | 174722-31-7 | 98% |
|
Rituximab (anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM. | ||||
T9907 | Nivolumab | 946414-94-4 | 98% |
|
Nivolumab (anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell... | ||||
T9920 | Evolocumab | 1256937-27-5 | 98% |
Evolocumab
|
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9). | ||||
T9905 | Cetuximab | 205923-56-4 | 98.00% |
|
Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, ... | ||||
T12177 | Natalizumab | 189261-10-7 | 98.00% |
|
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. | ||||
T9924 | Obinutuzumab | 949142-50-1 | 98.00% |
|
Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma. | ||||
T9909 | Pertuzumab | 380610-27-5 | 98.00% |
Pertuzumab
|
Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 t... | ||||
T9901 | Adalimumab | 331731-18-1 | 98.00% |
|
Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha. | ||||
T78269 | Anti-Mouse PD-1 Antibody (RMP1-14) | 98.01% |
Anti-Mouse PD-1 Antibody (RMP1-14)
|
|
RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling. | ||||
T9915 | Eculizumab | 219685-50-4 | 98.20% |
Eculizumab
|
Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5 | ||||
T9903 | Avelumab | 1537032-82-8 | 98.30% |
|
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity. | ||||
T37535 | Camrelizumab | 1798286-48-2 | 98.6% |
|
Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up ... | ||||
T9912 | Trastuzumab | 180288-69-1 | 99.00% |
|
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER... | ||||
T9930 | Secukinumab | 875356-43-7 | 99.10% |
Secukinumab
|
Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatme... | ||||
T9911 | Tocilizumab | 375823-41-9 | 99.50% |
|
Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor | ||||
T9906 | Ipilimumab | 477202-00-9 | 99.60% |
|
Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibit... | ||||
T9913 | Ustekinumab | 815610-63-0 | 99.70% |
|
Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody. | ||||
T9921 | Infliximab | 170277-31-3 | 99.70% |
|
Infliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis. | ||||
T9908 | Pembrolizumab | 1374853-91-4 | 99.70% |
Pembrolizumab
|
Pembrolizumab is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that i... | ||||
T76559 | Survodutide | 2805997-46-8 | 99.83% |
|
Survodutide (BI 456906) is a dual agonist of glucagon and glucagon-like peptide 1 (GLP-1) receptor (GLP Receptor) that reduces body weight in HbA1c16 diabetes. |